Immunotherapy before surgery for sarcomatoid pleural mesothelioma
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests adding immunotherapy before surgery to help patients with sarcomatoid pleural mesothelioma. The goal is to shrink or control the cancer and make surgery possible, while checking safety.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have sarcomatoid or mostly sarcomatoid pleural mesothelioma
- Your cancer is stage I to IIIA (by a standard tumor staging system)
- You have no prior treatment that would count as treatment for the main tumor
- You can have surgery: your cancer is resectable (removable) by the study surgeon
- You must not be pregnant or breastfeeding (and may need a recent negative pregnancy test)
- You must not have active autoimmune disease that needs treatment or a serious ongoing infection
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving chemotherapy and immunotherapy before planned surgery can make inoperable pleural mesothelioma operable. It is for people with a specific type of mesothelioma (epithelioid) that cannot be removed right away, to see if the treatment shrinks the tumor enough for surgery later.
This trial studies how well pembrolizumab (an immune therapy) works when added to chemotherapy before image-guided surgery for malignant pleural mesothelioma. It aims to shrink or control the cancer and improve surgical results by combining treatments.
This early-phase study tests a treatment that uses a patient’s immune cells (dendritic cell therapy) combined with surgery for epithelioid mesothelioma. It aims to help the immune system better recognize and attack the cancer after chemotherapy and before/around surgery.
This trial is testing a new immunotherapy drug (ivonescimab) combined with chemotherapy for people with mesothelioma that has already been treated. It aims to see if this combination can shrink tumors or slow the disease.
This Phase 1/2 study tests the immune medicines durvalumab and tremelimumab, with or without chemotherapy, given before surgery for mesothelioma. It aims to shrink the tumor and improve safety and outcomes so more patients can have their cancer fully removed.
This study tests whether atezolizumab given after surgery and chemotherapy can lower the risk of mesothelioma coming back compared with a placebo. It may help by boosting the immune system to control remaining microscopic cancer cells.
Hear when a new Pleural Biphasic Mesothelioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.